Request Demo
Last update 29 May 2025
ND-003 (NewDEL Biotech)
Last update 29 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms ND 003 (NewDEL Biotech), ND003 (NewDEL Biotech) |
Target |
Action inhibitors |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors), kinase inhibitor |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with ND-003 (NewDEL Biotech)ChiCTR2400086670
A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and food effects of single and multiple administration of ND-003 tablets in healthy adult volunteers
NCT06360874
Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Food Effect of ND-003 Tablets in Healthy Adult Volunteers
NCT06169579
A Single-arm, Non-randomized, Open-label, Dose-escalation and Dose-expansion, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles, as Well as Preliminary Efficacy, of ND-003 in Chinese Patients With Advanced Solid Tumors.
100 Clinical Results associated with ND-003 (NewDEL Biotech)
Login to view more data
100 Translational Medicine associated with ND-003 (NewDEL Biotech)
Login to view more data
100 Patents (Medical) associated with ND-003 (NewDEL Biotech)
Login to view more data
100 Deals associated with ND-003 (NewDEL Biotech)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatitis, Atopic | Phase 1 | China | 06 May 2024 | |
| Idiopathic Pulmonary Fibrosis | Phase 1 | China | 06 May 2024 | |
| Renal fibrosis | Phase 1 | China | 06 May 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 04 Feb 2024 | |
| Gastrointestinal Stromal Tumors | Phase 1 | China | - | |
| Neoplasms | IND Approval | United States | 13 Jul 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free